ARBOLT-H 20/12.5 mg Price

Overview

Welcome to Dwaey, specifically on ARBOLT-H 20/12.5 mg Tablet/Film coated page.
This medicine contains an important and useful components, as it consists of Olmesartan Medoxomil Ð Hydrochlorothiazide Ð.
ARBOLT-H 20/12.5 mg is available in the market in concentration 20 mg/tablet, 12.5 mg/tablet and in the form of Tablet/Film coated.

ANNORA PHARMA FZ-LLC is the producer of ARBOLT-H 20/12.5 mg and it is imported from UAE, The most popular alternatives of ARBOLT-H 20/12.5 mg are listed downward .

Mode Of Action

Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Indication

• Hypertension
• Diabetic nephropathy

Precaution

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: No human data; use with caution

Side Effects

• 1-10% Dizziness
• Headache
• Fatigue
• Diarrhea
• Hyperglycemia
• Hypertriglyceridemia
• Back pain
• Bronchitis
• Inflicted injury
• Flulike symptoms
• Pharyngitis
• Rhinitis
• Sinusitis
• Upper respiratory tract infection (URTI) Frequency Not Defined (selected) Anaphylactic reaction
• Angioedema
• Facial edema
• Rhabdomyolysis
• Hyperkalemia
• Tachycardia
• Hypercholesterolemia
• Gastroenteritis
• Hyperlipidemia Potentially Fatal: Acute renal failure.

Contra indication

Pregnancy (2nd and 3rd trimesters); biliary obstruction.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D